🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CQO (Chief Question Officer) has been spotted, the GU section of #ASCO24 has truly begun! Petros Grivas Toni Choueiri, MD Tom Powles Ignacio Duran Uromigos Enrique Grande Laura S. Mertens Matt Galsky

Important data by Matt Galsky et al. CM901 trial confirming better outcomes with LN-only mets in mUC (favorable prognostic factor across therapies). Impressive ORR, PFS, OS, DoCR in this subset. Similar concept in EV302 by Michiel van der Heijden #GU24 #ASCO24 OncoAlert ASCO Guru P. Sonpavde, MD

What a week it has been for #neoadjuvant #immunotherapy The Netherlands Cancer Institute . Discussing, working together and having fun with some of the greatest minds in the field across tumor types is an honor and a privilege! MarleenKokLab Christian Blank John Haanen Michiel van der Heijden #tinacascone

The European Commission has approved nivolumab paired with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. Michiel van der Heijden The Netherlands Cancer Institute #oncology #blcsm onclive.com/view/frontline…

Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…

Final team from @uromigos cup 🏆🏆🏆for #nashvillelive. Dutch 🇳🇱 🇳🇱 🇳🇱 team of Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions to get to Nashville podcasters.spotify.com/pod/show/the-u…

1/1 Today ✍️ Journal of Clinical Oncology Sometimes treating TNBC can be challenging. Nowadays, academic clin res to improve treatm for TNBC can also be challenging. How do we get from one-size fits all with 4 types of chemo plus 1yr of pembro to a personalized treatm? ascopubs.org/doi/10.1200/JC…

Platinum-based chemotherapy affects immune cell composition and tumor microenvironment in urothelial cancer. Increases in CD8+ T cells and PD-L1+ cells, but also fibroblast-based TGF-β signaling, may explain mixed results in clinical trials with chemo and immune checkpoint

Results of chemo+IO have produced inconsistent results in urothelial cancer. Opposing effects of pro- and anti-inflammatory changes may explain some of this. Uromigos Laura S. Mertens MarleenKokLab Myriam Chalabi Petros Grivas Matt Galsky The Netherlands Cancer Institute Tom Powles aacrjournals.org/clincancerres/…

Research from leila akkari's research group shows that white blood cells loaded with cholesterol play a critical role in the growth of #glioblastoma. These fat-laden macrophages influence the local immune response and help the tumor survive. Read more ➡️ bit.ly/3SNqMwZ

Looking forward to a fantastic ESMO - Eur. Oncology #esmo24 with fantastic speakers, excellent content, collaboration, exchange, mentorship & networking! Andres Cervantes George Pentheroudakis silke gillessen Tom Powles Toni Choueiri, MD FabriceAndre Matteo Lambertini, MD PhD Laurence Albiges Yohann Loriot Shilpa Gupta OncoAlert

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

🎓 In the NABUCCO study, PhD student Jeroen van Dorp Antoni van Leeuwenhoek, Universiteit Leiden LUMC Leiden found that immunotherapy can improve outcomes for advanced cases ➡️ bit.ly/3DU4u7S #PhD

#ASCO25 In cis-ineligible pts with mUC, 1L NIVO+IPI didn't show OS benefit vs gem-carbo. Still, long term efficacy favoured NIVO+IPI 🧠 Can early outcomes be boosted by integrating an ADC into an upfront CTLA4+PD-1 combo? VOLGA will evaluate this in MIBC Uromigos Michiel van der Heijden

Privilege to be one of the co-authors! CheckMate 901: NIVO+IPI vs Gem-Carbo in cisplatin-ineligible mUC. ✔ OS at 5 years: 23.0% vs 14.4% ✔ mOS: 19.1 vs 13.2 months (HR: 0.79) ✔ Durable responses even off-treatment But primary endpoint not met for PD-L1 ≥1% Presented by